MedTrace Logo

Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia

NCT01657955 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2012-08-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether bendamustine is effective in the treatment of initial treatment of Chronic Lymphocytic Leukemia (CLL).

Conditions

Interventions

DRUG

Bendamustine Hydrochloride Injection

DRUG

Chlorambucil

Sponsors & Collaborators

  • Shandong Lanjin Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Lu G Qiu, M.D. · Hematologic Hospital of Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-10-31
Completion
2013-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01657955 on ClinicalTrials.gov